Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Barclays PLC

Barclays PLC cut its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 27.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 171,196 shares of the biotechnology company’s stock after selling 66,407 shares during the quarter. Barclays PLC’s holdings in Blueprint Medicines were worth $15,836,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Wellington Management Group LLP lifted its stake in Blueprint Medicines by 22.5% during the third quarter. Wellington Management Group LLP now owns 3,964,610 shares of the biotechnology company’s stock valued at $366,726,000 after purchasing an additional 729,055 shares during the last quarter. Millennium Management LLC lifted its position in shares of Blueprint Medicines by 540.0% during the 2nd quarter. Millennium Management LLC now owns 627,626 shares of the biotechnology company’s stock valued at $67,646,000 after acquiring an additional 529,566 shares during the last quarter. 1832 Asset Management L.P. boosted its stake in shares of Blueprint Medicines by 200,159.4% during the 2nd quarter. 1832 Asset Management L.P. now owns 502,651 shares of the biotechnology company’s stock worth $54,176,000 after acquiring an additional 502,400 shares in the last quarter. State Street Corp grew its holdings in shares of Blueprint Medicines by 16.2% in the 3rd quarter. State Street Corp now owns 2,765,702 shares of the biotechnology company’s stock worth $255,827,000 after acquiring an additional 385,818 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its holdings in shares of Blueprint Medicines by 161.1% during the third quarter. Jacobs Levy Equity Management Inc. now owns 496,087 shares of the biotechnology company’s stock valued at $45,888,000 after purchasing an additional 306,079 shares during the last quarter.

Analyst Ratings Changes

Several analysts have issued reports on BPMC shares. UBS Group started coverage on Blueprint Medicines in a report on Thursday, October 24th. They set a “neutral” rating and a $88.00 price objective on the stock. StockNews.com upgraded shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Friday, November 8th. Guggenheim reiterated a “buy” rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. JMP Securities reissued a “market outperform” rating and set a $125.00 target price on shares of Blueprint Medicines in a research note on Monday, December 9th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $135.00 target price on shares of Blueprint Medicines in a research report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $122.11.

Insiders Place Their Bets

In related news, COO Christina Rossi sold 2,274 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $95.10, for a total value of $216,257.40. Following the transaction, the chief operating officer now directly owns 71,657 shares of the company’s stock, valued at approximately $6,814,580.70. This trade represents a 3.08 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Fouad Namouni sold 3,633 shares of the company’s stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $89.32, for a total value of $324,499.56. Following the sale, the insider now directly owns 69,070 shares of the company’s stock, valued at $6,169,332.40. The trade was a 5.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 8,260 shares of company stock valued at $768,057 over the last quarter. Insiders own 4.21% of the company’s stock.

Blueprint Medicines Trading Up 0.7 %

NASDAQ:BPMC opened at $93.19 on Monday. The company has a market capitalization of $5.92 billion, a P/E ratio of -44.17 and a beta of 0.59. The stock’s 50 day moving average price is $92.03 and its 200 day moving average price is $97.47. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.27 and a current ratio of 3.32. Blueprint Medicines Co. has a 52 week low of $72.24 and a 52 week high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($0.97) by $0.08. The company had revenue of $128.20 million for the quarter, compared to analyst estimates of $127.56 million. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. Blueprint Medicines’s quarterly revenue was up 126.5% on a year-over-year basis. During the same quarter in the prior year, the business posted ($2.20) EPS. On average, research analysts forecast that Blueprint Medicines Co. will post -3.68 EPS for the current fiscal year.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.